|Bid||17.49 x 1400|
|Ask||17.50 x 3100|
|Day's Range||17.39 - 17.60|
|52 Week Range||15.50 - 21.95|
|Beta (3Y Monthly)||0.94|
|PE Ratio (TTM)||21.53|
|Forward Dividend & Yield||0.79 (4.33%)|
|1y Target Est||25.31|
NEW YORK, NY / ACCESSWIRE / May 17, 2019 / Pomerantz LLP is investigating claims on behalf of investors of Takeda Pharmaceutical Company Limited ("Takeda" or the "Company") (NYSE: TAK). ...
Masakazu Takeda, portfolio manager of the Hennessy Japan Fund, looks for companies with global reach and business models that can withstand unexpected shocks. He likes Nidec, Fast Retailing and Recruit Holdings.
The Peninsula company is targeting the most prevalent acid-related disease in Western countries with a drug approved five years ago in Japan.
NEW YORK, May 16, 2019 -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Takeda Pharmaceutical Company Ltd. (“Takeda” or.
Japan's Takeda Pharmaceutical Co expects to receive binding offers for its Latin American business by the end of May, three sources with knowledge of the matter said. Brazilian pharmaceutical group EMS is considered the front-runner in the process, but Blackstone-backed Brazilian investment firm Patria Investments may also deliver a bid, sources added asking for anonymity as discussions are still private. Private equity firms such as Advent International Corp and CVC Capital Partners, and strategic bidders such as Brazilian pharmaceutical company Eurofarma, have analyzed the asset, but are not expected to deliver binding offers to the investment banking unit of Bank of America, which is Takeda's advisor.
– New Data to be Presented at the American Society of Clinical Oncology Annual Meeting and the Congress of the European Hematology Association Demonstrate Advancements
− 18 Takeda-sponsored abstracts investigating Entyvio® (vedolizumab) in ulcerative colitis (UC) and Crohn's disease (CD) will be presented − Research into investigational therapies and unmet needs in inflammatory ...
Takeda Pharmaceutical Company Limited (TOKYO:4502/NYSE:TAK) (“Takeda”) and the London School of Hygiene & Tropical Medicine (LSHTM) will announce today at the evening reception, hosted by the Embassy of Japan in the United Kingdom, the establishment of the Takeda Chair in Global Child Health, endowed by a £3 million donation by Takeda to LSHTM. The School’s first fully endowed corporate chair, it will support vital research into reducing 5.3 million child deaths in low and middle-income countries.
New Company and Collaboration To Develop Novel Therapeutics Including Vonoprazan for the Treatment of Acid-Related Disorders in North America and Europe
LEXINGTON, Mass., May 15, 2019 /PRNewswire/ -- Be #MPSAware for MPS Awareness Day 2019. Takeda is pleased to announce the return of the annual #MPSAware campaign to coincide with MPS Awareness Day on May 15th 2019. The campaign aims to raise awareness of this group of seven rare genetic diseases and to recognize the patients, carers and healthcare professionals living and working with MPS (mucopolysaccharidoses) diseases.
Japan's Nikkei ended higher in choppy trade on Wednesday, snapping a seven-day losing streak, as expectations that China could roll out fresh stimulus to prop up a slowing economy supported stocks in the region. "The market turned around on hopes that China will launch stimulus measures to tackle the weak economy, but the gains may be short-lived as it was just hopes at this point," said Yutaka Miura, a senior technical analyst at Mizuho Securities.
– Seven presentations will be shared, including new data on the risks of long-term cardiovascular, renal and infection complications, underlining Takeda’s commitment to further und
Japanese share prices were capped on Wednesday by concerns about the broader economic impact of rising tensions between Washington and Beijing, while an array of disappointing corporate earnings added to the downcast mood. The Nikkei share average was off 0.08% at 21,051, after spending much of the session under water, even after seven straight days of losses until Tuesday.
Takeda Pharmaceutical stock plunged Tuesday after the pharmaceutical company said it expects nearly $2 billion in operating losses this year related to its megamerger with Shire.
By Takashi Umekawa TOKYO (Reuters) - Takeda Pharmaceutical Co forecast an unexpected operating loss for the current year due to costs associated with the $59 billion purchase of Shire Plc, providing the ...
Takeda said it expects to post a significant operating loss in its coming financial year as a result of integration costs associated with its £46bn deal to buy Shire. The Japanese drugmaker forecast on ...
OSAKA, Japan-- -- Excellent FY2018 results driven by key growth products and strict Opex discipline, with Legacy Takeda 1 greatly exceeding original guidance and absorbing Shire acquisition-related costs In FY2019, continued momentum of key growth products in Takeda’s five key business areas 2 is expected to largely offset significant loss of exclusivity headwinds Strong base for future growth with ...
Nektar's (NKTR) earnings and sales beat estimates in the first quarter. The company is progressing well with its pipeline candidates.
Novartis gets a potentially blockbuster eye drug and Takeda gets to unload some debt and employees it took on when it purchased Shire.
TOKYO/ZURICH (Reuters) - Novartis is buying dry-eye drug Xiidra from Takeda Pharmaceutical Co for up to $5.3 billion as the Swiss drugmaker refreshes its ophthalmic medicines portfolio with a potential blockbuster. The deal, announced early on Thursday, calls for $3.4 billion up front and milestone payments up to $1.9 billion, Novartis said. The acquisition from Takeda, which is jettisoning the medicine to reduce debt, adds to several big Novartis transactions over the last year as the Basel-based company both beefs up its portfolio and sheds non-core assets to focus on prescription drugs.
OSAKA, Japan-- -- An additional treatment modality would provide more flexibility in how patients receive vedolizumab, a biologic with a gut-selective mode of action Vedolizumab set to be the only maintenance therapy to offer the option of intravenous or subcutaneous formulations for patients with ulcerative colitis Takeda Pharmaceutical Company Limited today announced that the U.S. Food & Drug Administration ...